

## INSULIN GLARGINE + LIXISENATIDE solution for injection (Suliqua® ▼)

G  
R  
E  
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of **INSULIN GLARGINE + LIXISENATIDE solution for injection (Suliqua® ▼)** for the treatment of type 2 diabetes mellitus

Suliqua® is licensed for use in combination with metformin to improve glycaemic control in adults with type 2 diabetes where this has not been provided by metformin alone or metformin combined with another oral glucose lowering agent or basal insulin.<sup>[1]</sup>

It is available as two pre-filled pen options that deliver different dose ranges:

- 100 units/ml + 50 micrograms/ml pre-filled pen delivers dose steps from 10-40 units of insulin glargine in combination with 5-20 micrograms lixisenatide (Suliqua® 10-40 pen)
- 100 units/ml + 33 micrograms/ml pre-filled pen delivers dose steps from 30-60 units of insulin glargine in combination with 10-20 micrograms lixisenatide (Suliqua® 30-60 pen).

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, clinicians should continue to prescribe GLP-1 mimetics in combination with insulin as the separate constituent products and in accordance with local and national guidelines:

- > Pan Mersey policy statement: [GLP-1 mimetics in combination with insulin](#) (last updated Sept 16)
- > NICE NG28: [Type 2 diabetes in adults: management](#) (last updated May 17)

### Reference

1. Sanofi. Summary of Product Characteristics: Suliqua. April 2017.  
Accessed 02 June 2017 at: <http://www.medicines.org.uk/emc/medicine/33221>

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.